763 Expanded and activated TILs kill tumor cells enabling IO compound assays. (10th December 2020)

• Record Type: Journal Article
• Authors: Pennacchi, Paula Comune; Navarro, Paloma; Navas, Verónica García; García, Arántzazu Barquín; Fernández, Elena Sevillano; Llorente, Sergio Ruiz; Rodriguez, Juan Francisco; Yagüe, Monica; Ballesteros, Joan; Primo, Daniel; Donas Jimenez, Jesus Garcia
• Is Part Of: Journal for immunotherapy of cancer. Volume 8(2020)Supplement 3
• Page Start: A457
• Page End: A457
• Publication Date: 2020-12-10
• Subjects: Cancer -- Immunotherapy -- Periodicals; Cancer -- Immunological aspects -- Periodicals; Tumors -- Immunological aspects -- Periodicals; Immunotherapy -- Periodicals; 616.99406105
• DOI: 10.1136/jitc-2020-SITC2020.0763
• Languages: English
• ISSNs: 2051-1426

Abstract

Abstract : Background: The Tumor Microenvironment (TME) has a key role in solid tumor therapy screening. We have developed a 3D ex vivo immunosuppressive assay mimicking the TME. It enables both allogenic & autologous tumor lysis by expanded Tumor Infiltrate Lymphocytes (TILs). It is a valuable 3D assay to study the activity of immune therapy drugs in patient sample. Methods: TME-aligned immunosuppressor media was produced by conditioned media from activated human Mesenchymal Stem Cells (hMSC). The TILs were expanded from patient-derived tumor samples and used for tumor killing potential evaluation. Target tumor cells were obtained from different sources: a) Isolated from patient-derived material and frozen until use in experiments with autologous or allogenic TILs or b) Tumor cell lines purchased from ATCC. The cells were mixed according to desired Effector:Target (E:T) ratios and embedded in 3D matrix in presence of TME-aligned media and immune therapy compounds, as Immune Checkpoint inhibitors (ImmChPi). The cell retrieval was performed at the end of desired timepoints and tumor cell killing and TILs activation profile were analyzed by flow cytometry. Results: The in vitro expanded TILs were able to kill autologous and allogenic tumor cells in several different E:T ratios within 24 hours. The% tumor cell killing for allogenic samples of the same cancer type showed a similar range as autologous killing. In a representative autologous E:T experiment we observed 40% of killing at E:T ratio 10:1 (figure 1 A). These same TILs showed even higher% tumor killing against allogenic tumor samples (up to 90%, data not shown). The Immune Check Point (ImmChP) expression during expansion may change and was followed to select proper expansion timelines. For example, in a particular ovarian cancer sample TIM3 was expressed in 75% of the expanded TILs (figure 1 B) and the treatment with TIM3 blocking antibody increased nearly 2-fold tumor cell killing in a dose dependent manner (figure 1 C). Conclusions: The Novel TME-Aligned 3D IO Assay is a reliable, and powerful tool to study the mode of action of tumor cells lysis by expanded TILs. Immune Therapy Drugs Screening can be performed in autologous or allogenic E:T conditions, allowing full mode of action description of Bi or Multispecific antibodies, ImmChPI and others, and opens a new door for therapy prediction studies in patient's material. Ethics Approval: The study was approved by Hospital 12 de Octubre Ethics Board, with approval number 14/199. Consent: Written informed consent was obtained from the patient for publication of this abstract and any accompanying images. A copy of the written consent is available for review by the Editor of this journal.